12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Safinamide: Additional Phase III data

Additional data from the double-blind, international Phase III SETTLE trial in 549 patients with mid- to late-stage idiopathic PD with motor fluctuations showed that once-daily 50-100 mg safinamide as an add-on to a stable dose of levodopa led to a >=20% improvement in UPDRS Part III in 127 of 274 patients vs. 96 of 275 patients for placebo plus levodopa (p=0.0062). Additionally, a greater number of patients receiving safinamide had a>=30% improvement in UPDRS...

Read the full 347 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >